Literature DB >> 10064632

Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults.

J Adelglass1, C A DeAbate, P McElvaine, C L Fowler, J LoCocco, T Campbell.   

Abstract

In this comparative trial, outpatients with acute sinusitis were randomly assigned to receive levofloxacin (500 mg orally once daily) or amoxicillin-clavulanate (500/125 mg orally 3 times daily) for 10 to 14 days. The success rates (cured and improved) 2 to 5 days after the end of treatment were 88.4% for the 267 clinically evaluable patients who received levofloxacin and 87.3% for the 268 clinically evaluable patients who received amoxicillin-clavulanate. Drug-related adverse events occurred in a smaller percentage of patients in the levofloxacin treatment group (7.4%) than in the amoxicillin-clavulanate treatment group (21.2%). The most common of these were nausea, diarrhea, vaginitis, and abdominal pain for levofloxacin-treated patients and diarrhea, vaginitis, nausea, genital moniliasis, abdominal pain, vomiting, and flatulence for amoxicillin-clavulanate-treated patients. The results of this study show that once-daily administration of levofloxacin is as effective and better tolerated than amoxicillin-clavulanate administered 3 times daily for treating acute sinusitis in adult outpatients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064632     DOI: 10.1016/S0194-5998(99)70269-X

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  8 in total

1.  Mirtazapine therapy for dysgeusia in an elderly patient.

Authors:  Kalpana P Padala; Cheryl K Hinners; Prasad R Padala
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 2.  Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.

Authors:  Drosos E Karageorgopoulos; Konstantina P Giannopoulou; Alexandros P Grammatikos; George Dimopoulos; Matthew E Falagas
Journal:  CMAJ       Date:  2008-03-25       Impact factor: 8.262

3.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

Review 4.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis.

Authors:  Nicole Mittmann; Farah Jivarj; Angelina Wong; Alice Yoon
Journal:  Can J Infect Dis       Date:  2002-09

Review 6.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.

Authors:  Jack B Anon
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.